Table 1.
Summary of studies finding statistically significant associations between genetic factors evaluated in the present study and inhibitor development in severe hemophilia A.
Fig 1.
Patient inclusion flow chart per site in association studies.
Table 2.
Univariate odds ratios for patient, disease and treatment risk factors for inhibitor development.
Table 3.
Univariate odds ratios for genetic risk factors of inhibitor development.
Table 4.
Adjusted odds ratios for patient, disease, treatment and genetic risk factors for inhibitor development.
Fig 2.
Optimal GPLTR tree associated with inhibitor development linearly adjusted on F8 mutation type, family history of inhibitors and type of FVIII product.
n represents number of patients among 125 patients included in the model.
Fig 3.
Deviance Importance Scores (DIS) obtained from bagged GPLTR for each of the competitive variables included in the multivariate model.